ZAI LAB LTD0000006 Cash Flow Conversion Efficiency
ZAI LAB LTD0000006 cash flow conversion efficiency. Based on the latest financial reports, ZAI LAB LTD0000006 (1ZLB) has a cash flow conversion efficiency ratio of -0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.91 Million ≈ $-13.93 Million USD) by net assets (€661.98 Million ≈ $773.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ZAI LAB LTD0000006 (2021–2025)
Cash flow conversion efficiency of ZAI LAB LTD0000006 from 2021 to 2025. This chart illustrates how ZAI LAB LTD0000006's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 1ZLB stock price for real-time trading data and today's change.
ZAI LAB LTD0000006 Cash Flow Conversion Ratio Explained
ZAI LAB LTD0000006 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ZAI LAB LTD0000006 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZAI LAB LTD0000006 ranked by their cash flow conversion efficiency. Also see market value of ZAI LAB LTD0000006 for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Jiuzhou Yi Gui Environmental Technology Co. Ltd.
SHG:688485
|
N/A |
|
Monadelphous Group Ltd
F:8MP
|
0.043x |
|
H&R Real Estate Investment Trust
TO:HR-UN
|
0.007x |
|
Ziff Davis Inc
NASDAQ:ZD
|
0.040x |
|
Zhejiang Transfar Co Ltd
SHE:002010
|
0.006x |
|
Parex Resources Inc
TO:PXT
|
0.082x |
|
Establishment Labs Holdings Inc
NASDAQ:ESTA
|
-0.768x |
|
Southchip Semiconductor Technology (Shanghai) Co. Ltd. A
SHG:688484
|
-0.024x |
Annual Cash Flow Conversion Efficiency for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual cash flow conversion efficiency of ZAI LAB LTD0000006 from 2021 to 2025. Review ZAI LAB LTD0000006 (1ZLB) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €715.50 Million ≈ $836.49 Million |
€-150.79 Million ≈ $-176.29 Million |
-0.211x | +17.52% |
| 2024-12-31 | €840.90 Million ≈ $983.10 Million |
€-214.87 Million ≈ $-251.20 Million |
-0.256x | -2.65% |
| 2023-12-31 | €796.12 Million ≈ $930.75 Million |
€-198.18 Million ≈ $-231.69 Million |
-0.249x | +29.20% |
| 2022-12-31 | €1.05 Billion ≈ $1.22 Billion |
€-367.64 Million ≈ $-429.81 Million |
-0.352x | +11.66% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
€-549.23 Million ≈ $-642.11 Million |
-0.398x | -- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more